Reimbursed Care Access in American Samoa

Currently classified as a strictly controlled substance under American Samoa law (listed among statutory “hallucinogens”), with criminal penalties for possession and no authorized medical use outside of approved clinical research. #.

Currently classified as a strictly controlled substance under national/territorial drug scheduling laws in American Samoa, with no authorized medical use outside of approved clinical research. #.

Esketamine (SPRAVATO®) is an FDA‑approved prescription nasal spray for treatment‑resistant depression and certain acute depressive symptoms; as an FDA‑approved product it may be lawfully used in U.S. territories subject to the same federal regulatory controls that apply in the states (including the SPRAVATO REMS program requiring administration in certified healthcare settings and post‑dose monitoring). # #.

Regulatory body and REMS: SPRAVATO is regulated by the U.S. Food and Drug Administration and distributed only through prescribers and clinics certified in the SPRAVATO REMS; clinics must monitor patients for adverse events (sedation, dissociation) for a minimum period after dosing. #.

Reimbursement / public vs private insurance in American Samoa: American Samoa’s Medicaid program operates under territory‑specific arrangements and waivers and therefore has different benefit design and funding rules compared with U.S. states; coverage decisions for high‑cost REMS‑restricted drugs like SPRAVATO are implemented at the territory program level and commonly require prior authorization, may be limited to care delivered at designated facilities (e.g., LBJ Hospital or approved off‑island providers), and may not mirror state Medicaid formularies or commercial insurance policies. Territory Medicaid programs have historically required prior authorization for some specialty services and used capped federal allotments and waiver authority that can restrict routine coverage available in the states. # #.

Practical access notes: Because SPRAVATO requires administration in REMS‑certified sites, local availability depends on whether an American Samoa provider has enrolled in the REMS and can meet monitoring/administration requirements. If local certified clinics are not available, patients typically must be referred off‑island for treatment and reimbursement would depend on the Medicaid State Agency policy or the patient’s private insurer and prior authorization status. Manufacturer assistance programs exist in the U.S. (for commercially insured patients), but eligibility and applicability for territory residents depend on program rules and payer status. #.

Federal scheduling and medical use: Ketamine (the racemate) is federally listed as a Schedule III controlled substance in the United States and therefore is a lawful prescription medicine for accepted medical uses (anesthesia, analgesia) under federal law; the DEA scheduling and federal rules apply in U.S. territories, including American Samoa. # #.

Clinical/off‑label psychiatric use and regulatory context: Ketamine is commonly used off‑label in the U.S. for treatment‑resistant depression and other psychiatric indications (infusions, intranasal compounded formulations), but the FDA has not approved racemic ketamine for these psychiatric indications; esketamine (SPRAVATO) is the FDA‑approved NMDA‑antagonist prescription product for TRD. Off‑label ketamine infusion programs operate in private clinics and reimbursement is highly variable; many insurers (including Medicaid programs) historically consider ketamine infusions for psychiatric indications experimental or non‑covered unless there is a specific policy or prior authorization in place. The FDA has warned about risks related to compounded ketamine nasal products and emphasized REMS controls for esketamine. # #.

Reimbursement and territory specifics: In American Samoa, Medicaid is administered under territory‑specific rules (waivers/allotment program) and coverage for off‑label ketamine psychiatric treatments is not guaranteed; when available, coverage is likely to require prior authorization, documentation of medical necessity (e.g., treatment‑resistant depression after two or more antidepressant failures), and may be limited to services provided at the LBJ Medical Center or approved off‑island referral sites. Commercial insurers’ coverage follows their own medical policy determinations; many commercial plans in the U.S. also do not routinely reimburse off‑label ketamine infusion for depression. Local providers and payers should be contacted for case‑specific determination. #.

Currently classified as a strictly controlled substance under American Samoa drug law (DMT/diethyltryptamine and related tryptamines are included in the territory’s hallucinogen listings), with no authorized medical use outside approved clinical research. #.

Currently classified as a strictly controlled substance in American Samoa’s hallucinogen provisions (tryptamines and related substances are listed), with no authorized medical use outside of approved clinical research. #.

Currently classified as a strictly controlled substance under American Samoa law (ibogaine explicitly listed in the hallucinogen statute), with no authorized medical use outside of approved clinical research. #.

American Samoa’s statute lists constituent hallucinogenic compounds (e.g., DMT and tryptamines) as controlled; ayahuasca preparations containing controlled tryptamines therefore fall under the territory’s prohibitions. There is no authorized medical use outside approved clinical research. #.

Mescaline and peyote are explicitly listed in American Samoa’s hallucinogen statute as controlled substances, with no authorized medical use outside of approved clinical research. #.

Compounds in the 2C family (2C‑X analogues such as 2C‑B/2C‑I/2C‑E etc.) and related substituted phenethylamines are covered by American Samoa’s hallucinogen controlled‑substance laws (listed generically by many amphetamine/phenethylamine designations); there is no authorized medical use outside of approved clinical research. #.